<DOC>
	<DOCNO>NCT02983227</DOCNO>
	<brief_summary>This Phase II , multicenter , open-label extension study evaluate long-term safety efficacy GDC-0853 participant moderate severe active RA complete 12 week study treatment Study GA29350 ( NCT02833350 ) . Eligible participant Study GA29350 elect participate receive treatment GDC-0853 twice daily ( BID ) open-label fashion 52 week , follow safety follow-up period 8 week .</brief_summary>
	<brief_title>A Study Evaluate Long-Term Safety Efficacy GDC-0853 Participants With Moderate Severe Rheumatoid Arthritis Enrolled Study GA29350 ( NCT02833350 )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Completion treatment specify Study GA29350 , include completion Day 84 study visit assessment Acceptable safety tolerability Study GA29350 determine investigator Medical Monitor Have receive prohibit medication Study GA29350 While take methotrexate , must willing receive oral folic acid ( least 5 milligram per week [ mg/week ] ) If receive oral corticosteroid ( less equal [ &lt; /= ] 10 milligram per day [ mg/day ] prednisone equivalent ) and/or nonsteroidal antiinflammatory drug , dos remain stable duration Study GA29350 Met protocol define treatment stop criterion Study GA29350 Treatment investigational agent ( i.e. , study drug ) live/attenuated vaccine prohibit medication Study GA29350 since last administration study drug Study GA29350 In opinion investigator , new ( since initially enrol Phase II Study GA29350 ) , significant , uncontrolled comorbidity would increase risk participant Study GA30067 Pregnant lactating , intend become pregnant study Participants experience de novo reactivate serious viral infection hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) Phase II Study GA29350 Any major episode infection require hospitalization treatment intravenous antibiotic Phase II Study GA29350 Participants develop malignancy Phase II Study GA29350 12lead electrocardiogram ( ECG ) Day 84 Study GA29350 demonstrate clinically relevant abnormality may affect participant safety interpretation study result Current treatment medication well know prolong QT interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>